BRIDGEBIO PHARMA INC (BBIO) Fundamental Analysis & Valuation

NASDAQ:BBIO • US10806X1028

66.54 USD
+2.01 (+3.11%)
At close: Mar 4, 2026
66.54 USD
0 (0%)
After Hours: 3/4/2026, 8:09:44 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BBIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BBIO. BBIO was compared to 520 industry peers in the Biotechnology industry. BBIO may be in some trouble as it scores bad on both profitability and health. BBIO shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

1

1. BBIO Profitability Analysis

1.1 Basic Checks

  • In the past year BBIO has reported negative net income.
  • In the past year BBIO has reported a negative cash flow from operations.
  • BBIO had negative earnings in each of the past 5 years.
  • BBIO had a negative operating cash flow in each of the past 5 years.
BBIO Yearly Net Income VS EBIT VS OCF VS FCFBBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200M -400M -600M

1.2 Ratios

  • BBIO has a worse Return On Assets (-77.45%) than 65.58% of its industry peers.
Industry RankSector Rank
ROA -77.45%
ROE N/A
ROIC N/A
ROA(3y)-84.48%
ROA(5y)-77.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBIO Yearly ROA, ROE, ROICBBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

1.3 Margins

  • The Gross Margin of BBIO (95.82%) is better than 95.58% of its industry peers.
  • In the last couple of years the Gross Margin of BBIO has remained more or less at the same level.
  • BBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.85%
BBIO Yearly Profit, Operating, Gross MarginsBBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. BBIO Health Analysis

2.1 Basic Checks

  • BBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BBIO has more shares outstanding
  • The number of shares outstanding for BBIO has been increased compared to 5 years ago.
  • Compared to 1 year ago, BBIO has a worse debt to assets ratio.
BBIO Yearly Shares OutstandingBBIO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
BBIO Yearly Total Debt VS Total AssetsBBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • BBIO has an Altman-Z score of -3.81. This is a bad value and indicates that BBIO is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -3.81, BBIO is in line with its industry, outperforming 43.08% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.81
ROIC/WACCN/A
WACC7.78%
BBIO Yearly LT Debt VS Equity VS FCFBBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B -1B 2B -2B

2.3 Liquidity

  • A Current Ratio of 2.77 indicates that BBIO has no problem at all paying its short term obligations.
  • BBIO has a Current ratio of 2.77. This is in the lower half of the industry: BBIO underperforms 66.92% of its industry peers.
  • A Quick Ratio of 2.68 indicates that BBIO has no problem at all paying its short term obligations.
  • The Quick ratio of BBIO (2.68) is worse than 66.35% of its industry peers.
Industry RankSector Rank
Current Ratio 2.77
Quick Ratio 2.68
BBIO Yearly Current Assets VS Current LiabilitesBBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. BBIO Growth Analysis

3.1 Past

  • BBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.33%.
  • The Revenue has grown by 126.26% in the past year. This is a very strong growth!
  • Measured over the past years, BBIO shows a very strong growth in Revenue. The Revenue has been growing by 127.44% on average per year.
EPS 1Y (TTM)-22.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)126.26%
Revenue growth 3Y86.3%
Revenue growth 5Y127.44%
Sales Q2Q%2521.18%

3.2 Future

  • Based on estimates for the next years, BBIO will show a very strong growth in Earnings Per Share. The EPS will grow by 39.90% on average per year.
  • BBIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 52.08% yearly.
EPS Next Y50.16%
EPS Next 2Y47.24%
EPS Next 3Y44.58%
EPS Next 5Y39.9%
Revenue Next Year86.86%
Revenue Next 2Y80.38%
Revenue Next 3Y69.56%
Revenue Next 5Y52.08%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BBIO Yearly Revenue VS EstimatesBBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B
BBIO Yearly EPS VS EstimatesBBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. BBIO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BBIO. In the last year negative earnings were reported.
  • Also next year BBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBIO Price Earnings VS Forward Price EarningsBBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBIO Per share dataBBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BBIO's earnings are expected to grow with 44.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.24%
EPS Next 3Y44.58%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BBIO Dividend Analysis

5.1 Amount

  • BBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BBIO Fundamentals: All Metrics, Ratios and Statistics

BRIDGEBIO PHARMA INC

NASDAQ:BBIO (3/4/2026, 8:09:44 PM)

After market: 66.54 0 (0%)

66.54

+2.01 (+3.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)04-27
Inst Owners91.39%
Inst Owner Change7.94%
Ins Owners4.09%
Ins Owner Change-3.39%
Market Cap12.90B
Revenue(TTM)502.08M
Net Income(TTM)-724.93M
Analysts85
Price Target99.16 (49.02%)
Short Float %12.61%
Short Ratio7.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.46%
Min EPS beat(2)-32.11%
Max EPS beat(2)-4.81%
EPS beat(4)1
Avg EPS beat(4)-10.2%
Min EPS beat(4)-32.11%
Max EPS beat(4)6.56%
EPS beat(8)3
Avg EPS beat(8)8.26%
EPS beat(12)3
Avg EPS beat(12)0.75%
EPS beat(16)5
Avg EPS beat(16)5.97%
Revenue beat(2)2
Avg Revenue beat(2)7.09%
Min Revenue beat(2)2.94%
Max Revenue beat(2)11.23%
Revenue beat(4)4
Avg Revenue beat(4)29.34%
Min Revenue beat(4)2.94%
Max Revenue beat(4)84.61%
Revenue beat(8)6
Avg Revenue beat(8)186.1%
Revenue beat(12)6
Avg Revenue beat(12)110.2%
Revenue beat(16)7
Avg Revenue beat(16)90.77%
PT rev (1m)9.49%
PT rev (3m)19.61%
EPS NQ rev (1m)-3.38%
EPS NQ rev (3m)-1.43%
EPS NY rev (1m)1.91%
EPS NY rev (3m)5.88%
Revenue NQ rev (1m)0.77%
Revenue NQ rev (3m)2.14%
Revenue NY rev (1m)2.38%
Revenue NY rev (3m)8.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.69
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.78
EYN/A
EPS(NY)-1.88
Fwd EYN/A
FCF(TTM)-2.35
FCFYN/A
OCF(TTM)-2.3
OCFYN/A
SpS2.59
BVpS-10.76
TBVpS-10.91
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -77.45%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.82%
FCFM N/A
ROA(3y)-84.48%
ROA(5y)-77.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.85%
F-Score3
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 176.52%
Cap/Sales 1.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.77
Quick Ratio 2.68
Altman-Z -3.81
F-Score3
WACC7.78%
ROIC/WACCN/A
Cap/Depr(3y)114.42%
Cap/Depr(5y)132.7%
Cap/Sales(3y)6.65%
Cap/Sales(5y)9.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y50.16%
EPS Next 2Y47.24%
EPS Next 3Y44.58%
EPS Next 5Y39.9%
Revenue 1Y (TTM)126.26%
Revenue growth 3Y86.3%
Revenue growth 5Y127.44%
Sales Q2Q%2521.18%
Revenue Next Year86.86%
Revenue Next 2Y80.38%
Revenue Next 3Y69.56%
Revenue Next 5Y52.08%
EBIT growth 1Y13.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.91%
EBIT Next 3Y48.24%
EBIT Next 5Y33.16%
FCF growth 1Y14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.37%
OCF growth 3YN/A
OCF growth 5YN/A

BRIDGEBIO PHARMA INC / BBIO FAQ

What is the fundamental rating for BBIO stock?

ChartMill assigns a fundamental rating of 3 / 10 to BBIO.


What is the valuation status for BBIO stock?

ChartMill assigns a valuation rating of 1 / 10 to BRIDGEBIO PHARMA INC (BBIO). This can be considered as Overvalued.


Can you provide the profitability details for BRIDGEBIO PHARMA INC?

BRIDGEBIO PHARMA INC (BBIO) has a profitability rating of 1 / 10.


Can you provide the financial health for BBIO stock?

The financial health rating of BRIDGEBIO PHARMA INC (BBIO) is 2 / 10.